According to the available data, SGLT2 inhibitors can significantly prevent or reduce cardiovascular diseases and kidney abnormalities in patients with type 2 diabetes mellitus with tolerable safety outcomes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.